Article

Early rheumatologist evaluation of RA improves outcomes

For patients with rheumatoid arthritis (RA), a shorter time to assessment by a rheumatologist is associated with longer disease-modifying antirheumatic drug (DMARD)-free remission times and less joint destruction.

For patients with rheumatoid arthritis (RA), a shorter time to assessment by a rheumatologist is associated with longer disease-modifying antirheumatic drug (DMARD)-free remission times and less joint destruction. However, patients with early arthritis who have a diagnosis of RA experience one of the longest delays and only one-third are assessed within the “window of opportunity.”

van der Linden and associates evaluated patient, general practitioner (GP), and rheumatologist delay in 1674 patients with early arthritis; 598 had RA. The latter patients were evaluated for the relationships among total delay, achievement of DMARD-free remission, and rate of joint destruction over 6 years.

Among patients with early arthritis, the average patient, GP, and rheumatologist delays were 2.4, 8.0, and 13.7 weeks, respectively. Among persons with RA, the delay was longest at 18 weeks; most (67%) of these patients were seen 12 weeks or longer after receiving the diagnosis, and they had a hazard ratio of 1.87 for failure to achieve DMARD-free remission. They also had 1.3 times more joint destruction over 6 years than persons seen before 12 weeks.

The authors noted that diminishing the delay in assessment by a rheumatologist will be crucial to further improvement in disease outcomes.

Related Videos
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
© 2025 MJH Life Sciences

All rights reserved.